Safety and efficacy clinical trials for SYL1001, a novel short interfering RNA for the treatment of dry eye disease
Autor (es)
Benitez-Del-Castillo, José Manuel; Moreno-Montañés, Javier; Jiménez-Alfaro, Ignacio; Muñoz-Negrete, Francisco José; Turman, Krista; Palumaa, Kadi; Sádaba, Belén; González, María Victoria; Ruz, Verónica; Vargas, Beatriz; Pañeda, Covadonga; Martínez, Tamara; Bleau, Anne Marie; Jimenez, Ana IsabelEntidad
UAM. Departamento de Cirugía; Instituto de Investigación Sanitaria Fundación Jiménez Díaz (IIS-FJD)Editor
Association for Research in Vision and OphthalmologyFecha de edición
2016-11-01Cita
10.1167/ iovs.16-20303
Investigative Ophthalmology & Visual Science 57.14 (2016): 6447-6454
ISSN
0146-0404DOI
10.1167/ iovs.16-20303Financiado por
Supported by a grant from the 2012 INNPACTO program of the Spanish Ministry of Science and Innovation: INDREYE (Innovative solutions for the treatment and diagnosis of dry eye disease) grant number IPT-2012-0438-010000 (Madrid, Spain).Proyecto
Gobierno de España. IPT-2012-0438-010000; Gobierno de España. INNPACTO 2012Versión del editor
https://doi.org/10.1167/ iovs.16-20303Materias
Dry eye disease; Ocular pain; siRNA; Visual analogue scale; MedicinaDerechos
© 2016, Association for Research in Vision and Ophthalmology Inc.Resumen
PURPOSE. To evaluate the efficacy and safety of SYL1001, a short interfering (si) RNA targeting the transient receptor potential cation channel subfamily V member 1 (TRPV1), for the treatment of dry eye disease (DED). METHODS. This study combines a phase I and two phase II clinical trials to test different doses of SYL1001 in a total of 156 healthy subjects and patients with DED. After 10 days of treatment, the primary efficacy endpoints were the effect on (1) the scoring in the Visual Analogue Scale (VAS) and Ocular Surface Disease Index (OSDI) questionnaires, and (2) ocular tolerance evaluated by corneal fluorescein staining and conjunctival hyperemia. Secondary endpoints included the assessment of systemic and local tolerance. RESULTS. Topical administration of SYL1001 1.125% once daily produced a significant decrease in VAS scores compared with placebo from day 4 until the end of treatment (change from baseline at day 10: -1.73 ± 0.32 vs. -0.91 ± 0.34; P = 0.013). For all treatments, OSDI scores were significantly reduced compared to their respective baseline values (P < 0.01), although no significant changes were detected between groups. Conjunctival hyperemia (quantified as normal or abnormal) significantly improved after instillation of SYL1001 1.125% compared with placebo (50% vs. 20%; P < 0.05). Excellent tolerability was reported, with no differences in the rates of occurrence of adverse events between groups. CONCLUSION. These trials achieved their primary endpoints of identifying the most effective dose of SYL1001 (1.125%). SYL1001 showed a large safety margin and may provide novel therapeutic opportunity for the relief of dry eye. (ClinicalTrials.gov numbers, NCT01438281, NCT01776658, and NCT02455999.)
Eliminar seleccionado
Lista de ficheros
Google Scholar:Benitez-Del-Castillo, José Manuel
-
Moreno-Montañés, Javier
-
Jiménez-Alfaro, Ignacio
-
Muñoz-Negrete, Francisco José
-
Turman, Krista
-
Palumaa, Kadi
-
Sádaba, Belén
-
González, María Victoria
-
Ruz, Verónica
-
Vargas, Beatriz
-
Pañeda, Covadonga
-
Martínez, Tamara
-
Bleau, Anne Marie
-
Jimenez, Ana Isabel
Lista de colecciones del ítem
Registros relacionados
Mostrando ítems relacionados por título, autor, creador y materia.
-
Clinical efficacy and safety of fanhdi<sup>®</sup>, a plasma-derived VWF/Factor VIII concentrate, in von willebrand disease in Spain: a retrospective study
Jiménez Yuste, Víctor Manuel; Álvarez Roman, María Teresa; Palomo Bravo, Ángeles; Galmes, Bernardo J.; Nieto Hernández, Maria del Mar; Benítez Hidalgo, Olga; Marzo Alonso, Cristina; Pérez González, Noelia Florencia; Coll, Julia; Núñez, Ramiro; Carrasco, Marina; García Candel, Faustino; Gonzalez-Porras, Jose Ramon; Hernández García, Carmen; Varó Castro, Maria José; Mir, Roser
2022-01-02